Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021
- Wall St set to open higher after bumper earnings from big banks
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Dollar heads for second week of losses as yields decline
- Morgan Stanley (MS) Tops Q1 EPS by 52c
- Apple (AAPL) May Scrap iPhone Mini Next Year, New Lineup to Focus on Camera Quality, Says Top Analyst
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33rd Annual Roth Conference being held virtually from March 15th – March 17th, 2021.
This year’s event will consist of 1-on-1 / small group meetings, analyst-selected virtual fireside chats, thematic industry panels, and selected Companies on-demand presentations. Institutional investors interested in one-on-one meetings with Medexus management should contact their ROTH Capital institutional sales representative.
About Medexus Pharmaceuticals Inc.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
For more information, please contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: firstname.lastname@example.org
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: email@example.com
Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020E-mail: firstname.lastname@example.org
Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: email@example.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reporting of trading in Tryg shares by Elias Bakk
- Net Asset Value(s)
- Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021